AumniVIDA

Triglycerides (Triglycerides)

Updated October 31, 2026 · 43 sources · Written by the AumniVIDA team

Units

What is Triglycerides?

Triglycerides are the main form of fat in the body and in the blood, carried by VLDL from the liver and chylomicrons from the gut. A standard lipid panel measures them: under 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) is normal, 500 mg/dL (5.6 mmol/L)5.6 mmol/L (500 mg/dL) or more is very high, and levels near 1,000 mg/dL risk pancreatitis.

Cutaway illustration of liver cells beside a small blood vessel, releasing large, round, fat-filled particles into the bloodstream, with a few smaller particles further downstream.
The liver packs triglycerides into VLDL particles and releases them into the blood, where an enzyme on vessel walls starts emptying them.

Questions people ask about Triglycerides

  1. 01What do high triglycerides mean?High triglycerides mean your blood carries more triglyceride-rich particles than guidelines consider normal: 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) or more when fasting. From 150 to 499 mg/dL the concern is heart disease. At 500 mg/dL (5.6 mmol/L)5.6 mmol/L (500 mg/dL), and especially 1,000 mg/dL (11.3 mmol/L)11.3 mmol/L (1,000 mg/dL) or more, pancreatitis becomes the main risk.Read the answer
  2. 02How to lower triglyceridesTo lower triglycerides, lose 5 to 10% of body weight if you carry extra (about 20% lower), cut sugar, refined starch and alcohol (about 10 to 20% lower) and do regular aerobic exercise. Statins lower them by 15 to 31%, prescription omega-3 by 30% or more at very high levels, and newer apoC-III drugs by more than half.Read the answer
  3. 03What is a normal triglyceride level?A normal fasting triglyceride level is under 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) in US and European guidance, and under 100 mg/dL (1.2 mmol/L)1.2 mmol/L (100 mg/dL) is optimal.Read the answer
  4. 04Triglyceride to HDL ratio: what it tells youThe triglyceride to HDL ratio is triglycerides divided by HDL cholesterol from a standard lipid panel.Read the answer
  5. 05What do low triglycerides mean?Low triglycerides, well below 100 mg/dL (1.1 mmol/L)1.1 mmol/L (100 mg/dL), usually reflect efficient fat clearance from leanness, exercise, low-carbohydrate eating or protective genes, and come with lower heart risk.Read the answer

Key takeaways

  1. 1

    Under 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) is normal in most guidelines, 500 mg/dL (5.6 mmol/L)5.6 mmol/L (500 mg/dL) or more is very high, and the European consensus calls under 100 mg/dL (1.2 mmol/L)1.2 mmol/L (100 mg/dL) optimal [1] [2].

  2. 2

    You usually do not need to fast: ordinary meals raise triglycerides by at most about 26 mg/dL (0.3 mmol/L)0.3 mmol/L (26 mg/dL) on average [3].

  3. 3

    Triglyceride-rich particles and their remnants appear to cause heart disease, but the benefit of lowering them tracks the drop in ApoB [4] [5].

  4. 4

    Pancreatitis risk rises steadily with triglycerides and becomes the main concern near 880 to 1,000 mg/dL (10 to 11.3 mmol/L)10 to 11.3 mmol/L (880 to 1,000 mg/dL) [6] [7].

  5. 5

    Weight loss of 5 to 10% lowers triglycerides by about 20%, and cutting sugar, refined starch and alcohol by about 10 to 20% [1].

  6. 6

    Lowering triglycerides with drugs did not always prevent heart events: icosapent ethyl did in REDUCE-IT, while STRENGTH and PROMINENT found no benefit [8] [9] [10].

What are triglycerides?

Triglycerides are fat molecules: a glycerol backbone carrying three fatty acids. The body stores spare energy as triglycerides in fat tissue and moves them through the blood inside lipoprotein particles, so a blood test shows how much fat is in transit at that moment.

Triglycerides are the main fat in food and in body fat. When you eat more energy than you burn, the liver and fat tissue store it as triglycerides. Between meals, fat tissue releases fatty acids for muscles and the heart to burn.

Triglycerides vs cholesterol

Cholesterol is a waxy building material for cell membranes and hormones; triglycerides are fuel. Neither dissolves in blood, so both ride in the same lipoprotein particles. A standard lipid panel measures total cholesterol, HDL cholesterol and triglycerides directly, and usually calculates LDL cholesterol from them with the Friedewald equation: total cholesterol minus HDL minus triglycerides divided by 5 (mg/dL) or by 2.2 (mmol/L). That shortcut is only used when triglycerides are below 400 mg/dL (4.5 mmol/L)4.5 mmol/L (400 mg/dL) [3]. Above that, labs measure LDL directly. See the LDL cholesterol and ApoB guides for how those numbers relate.

How common are high triglycerides?

In US national survey data from 2001 to 2006, 32% of adults had triglycerides of 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) or more: 14% borderline high, 16% high and about 2% very high [1]. In Copenhagen, 27% of adults have nonfasting triglycerides above 176 mg/dL (2 mmol/L)2 mmol/L (176 mg/dL) [11].

Units

US labs report mg/dL; most other countries report mmol/L. Divide mg/dL by 88.57 to get mmol/L, or multiply mmol/L by 88.57 to get mg/dL. So 150 mg/dL is 1.7 mmol/L and 500 mg/dL is 5.6 mmol/L.

How does the body make and carry triglycerides?

The gut packs fat from meals into chylomicrons, and the liver packs fat into VLDL particles. An enzyme on blood vessel walls, lipoprotein lipase, strips triglycerides out for muscle and fat tissue, leaving smaller, cholesterol-rich remnants that the liver clears.

Two kinds of triglyceride-rich particles carry almost all the triglycerides in your blood [2]:

  • Chylomicrons come from the small intestine after a meal and carry dietary fat. Each carries one copy of apolipoprotein B48.
  • VLDL (very low-density lipoprotein) comes from the liver. Each carries one copy of ApoB100. The liver builds VLDL triglycerides from fat it makes itself from carbohydrate (de novo lipogenesis), from fatty acids released by fat tissue and from fat returned in remnant particles.

Lipoprotein lipase empties the particles

Lipoprotein lipase sits on the inner surface of capillaries in muscle and fat tissue and breaks triglycerides into fatty acids that the tissues take up. ApoC-II switches the enzyme on. ApoC-III and the proteins ANGPTL3, 4 and 8 slow it down [2]. As the particles empty, they shrink into remnants: smaller, denser and richer in cholesterol. A remnant can carry up to four times as much cholesterol per particle as LDL [2].

Why insulin resistance raises triglycerides

Insulin resistance pushes VLDL output up in three ways: insulin-resistant fat cells release more fatty acids, more remnant fat returns to the liver, and the liver makes more fat from scratch. People with insulin resistance and obesity also carry more apoC-III, which slows clearance [2]. Moderately high triglycerides usually reflect overproduction; severe elevations usually reflect failed clearance by lipoprotein lipase [2]. That is why triglycerides travel with liver fat, fasting insulin and HbA1c.

How long the particles last

Chylomicrons and VLDL circulate for 4 to 13 hours in people with raised triglycerides, while LDL lasts 2.5 to 3.5 days [2]. That short life is why triglycerides respond to meals, alcohol and lifestyle changes faster than LDL cholesterol does. Across the population, levels range from about 30 to 10,000 mg/dL (0.33 to 120 mmol/L)0.33 to 120 mmol/L (30 to 10,000 mg/dL) [2].

Flat illustration of a row of round particles going from large and pale to small and dark from left to right, the smallest slipping through a gap in a wall.
As lipoprotein lipase empties triglyceride from VLDL and chylomicrons, the particles shrink into remnants that hold more cholesterol per particle and can enter the artery wall.

Why do triglycerides matter for heart disease?

High triglycerides mark a surplus of triglyceride-rich particles and their remnants, which carry cholesterol into artery walls. Genetic studies suggest these particles cause heart disease, but the risk tracks the number of ApoB particles more closely than the triglyceride number itself.

What the cohort studies show

In 29 prospective studies with 262,525 people, those in the top third of triglycerides had 1.72 times the odds of coronary heart disease of those in the bottom third after adjustment for established risk factors [12]. In Copenhagen, women with nonfasting triglycerides of 443 mg/dL (5 mmol/L)5 mmol/L (443 mg/dL) or more had 5.4 times the adjusted risk of a heart attack of women under 89 mg/dL (1 mmol/L)1 mmol/L (89 mg/dL) [13].

The association is tangled with other lipids. In a pooled analysis of 302,430 people, the link between triglycerides and coronary disease disappeared (hazard ratio 0.99) once HDL and non-HDL cholesterol were taken into account [14].

What genetics adds

Mendelian randomization uses inherited variants as a natural experiment. Variants that raise triglycerides raise coronary risk in proportion to their triglyceride effect [15]. A genetically 39 mg/dL (1 mmol/L)1 mmol/L (39 mg/dL) higher remnant cholesterol carried a 2.8-fold causal risk of ischemic heart disease [4]. People born with a broken APOC3 gene have 39% lower triglycerides and a 40% lower risk of coronary disease [16].

The key refinement: triglyceride-lowering and LDL-lowering variants gave the same coronary benefit per 10 mg/dL lower ApoB, and the triglyceride effect vanished once ApoB was accounted for [5]. A separate multivariable analysis found that only ApoB kept a robust effect [17]. Each VLDL and remnant particle carries one ApoB, so ApoB counts the particles that do the damage. The ApoB guide explains the test.

Triglyceride-rich lipoproteins also appear to cause low-grade inflammation [11], one reason triglycerides and hs-CRP often rise together.

Pancreatitis at very high levels

Very high triglycerides threaten the pancreas rather than the arteries. The European Atherosclerosis Society puts the high-risk line at 880 mg/dL (10 mmol/L)10 mmol/L (880 mg/dL) [2]. Risk climbs earlier, though: in 116,550 Danes, people with nonfasting triglycerides of 443 mg/dL (5 mmol/L)5 mmol/L (443 mg/dL) or more had 8.7 times the pancreatitis risk of those under 89 mg/dL [6]. The high triglycerides page covers this range in detail.

Acute pancreatitis risk by nonfasting triglyceride level

Show the data
Acute pancreatitis risk by nonfasting triglyceride level
ItemValue (times the risk)LowHighNote
89 to 176 mg/dL (1 to 1.99 mmol/L)1.612.6
177 to 265 mg/dL (2 to 2.99 mmol/L)2.31.34
266 to 353 mg/dL (3 to 3.99 mmol/L)2.91.45.9
354 to 442 mg/dL (4 to 4.99 mmol/L)3.91.510
443 mg/dL (5 mmol/L) or more8.73.720
Pancreatitis risk climbs well before the very high range: at 443 mg/dL (5 mmol/L) or more it was 8.7 times that of people under 89 mg/dL.

Do you need to fast before a triglyceride test?

Usually not. After ordinary meals, triglycerides rise on average by at most about 26 mg/dL (0.3 mmol/L)0.3 mmol/L (26 mg/dL), which European and US guidance treat as minor. A fasting repeat makes sense when a nonfasting result is above 440 mg/dL (5 mmol/L)5 mmol/L (440 mg/dL) or when very high levels are being followed.

A joint European consensus reviewed large population studies and found the maximal mean change 1 to 6 hours after habitual meals was +26 mg/dL (+0.3 mmol/L) for triglycerides, with smaller shifts in the cholesterol numbers [3]. It recommends nonfasting lipid profiles for most people and suggests a fasting repeat when nonfasting triglycerides exceed 440 mg/dL (5 mmol/L)5 mmol/L (440 mg/dL), in known hypertriglyceridemia, after pancreatitis caused by triglycerides, or when starting a drug that can raise triglycerides sharply [3]. The 2018 US cholesterol guideline also accepts fasting or nonfasting measurement for screening [18].

Nonfasting values are not a lesser measurement. In the Women's Health Study, nonfasting triglycerides predicted cardiovascular events independently of other risk factors, most strongly 2 to 4 hours after a meal, while fasting levels added little once other factors were counted [19]. In pooled data, nonfasting samples predicted risk at least as well as fasting ones [14].

Different flags for fasting and nonfasting samples

Labs following the European consensus flag a nonfasting triglyceride of 175 mg/dL (2 mmol/L)2 mmol/L (175 mg/dL) or more, and a fasting value of 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) or more [3]. A traditional fast is 8 to 12 hours, with water allowed [3].

The Endocrine Society takes a stricter line: it recommends diagnosing hypertriglyceridemia on fasting levels [20]. If your clinician asks for a fasting test, that is why.

What happens to triglycerides after a meal

  1. 0 hoursAn ordinary mealTriglycerides start to rise from the fasting baseline.
  2. 1 to 6 hoursPeak riseThe maximal mean rise after habitual meals is 26 mg/dL (0.3 mmol/L)0.3 mmol/L (26 mg/dL).
  3. 2 to 4 hoursBest window for predicting riskNonfasting values here best predicted cardiovascular events in the Women's Health Study.
  4. 8 to 12 hoursFasting stateA traditional fast, with water allowed.

A very fatty meal pushes the rise higher. Retest fasting if a nonfasting value is above 440 mg/dL (5 mmol/L)5 mmol/L (440 mg/dL) (Nordestgaard 2016).

After an ordinary meal, triglycerides rise for a few hours and then fall back; the average peak is small, which is why most labs accept nonfasting samples.

What is a normal triglyceride level?

Most guidelines call a fasting level under 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) normal and 500 mg/dL (5.6 mmol/L)5.6 mmol/L (500 mg/dL) or more very high. The European Atherosclerosis Society calls under 100 mg/dL (1.2 mmol/L)1.2 mmol/L (100 mg/dL) optimal, because remnant particles start to build up above that.

Guidelines agree on the main lines but name the bands differently. The table puts them side by side in both units. US bodies use 150, 200 and 500 mg/dL [1]; the 2026 US guideline groups 150 to 499 mg/dL as mild to moderate and treats 500 mg/dL and above as severe, with 1,000 mg/dL as the point where pancreatitis prevention becomes urgent [7]. The European consensus adds an optimal band under 100 mg/dL and sets the extreme band at 880 mg/dL [2]. The Endocrine Society uses 1,000 mg/dL as its line for severe disease [20].

The European choice of 100 mg/dL has a biological reason: remnant particles start to accumulate at fasting levels above about 100 mg/dL (1.2 mmol/L)1.2 mmol/L (100 mg/dL), and heart risk becomes clinically relevant above 150 mg/dL (1.7 mmol/L)1.7 mmol/L (150 mg/dL) [2]. The 2018 US guideline treats persistent levels of 175 mg/dL (1.97 mmol/L)1.97 mmol/L (175 mg/dL) or more as a factor that can tip a decision toward a statin [18].

The cut points are the same for adult women and men and do not change with age. The normal range page covers age, sex and fasting in detail.

Triglyceride categories by guideline, fasting values in mg/dL with mmol/L in brackets. Compiled by AumniVIDA from the cited guidelines and reviews. [1]
GuidelineNormal or optimalBorderlineHighVery high or severe
AHA scientific statement (2011)Optimal under 100 (1.1); normal under 150 (1.7)150 to 199 (1.7 to 2.2)200 to 499 (2.3 to 5.6)500 or more (5.6 or more)
National Lipid Association (2015)Under 150 (1.7)150 to 199 (1.7 to 2.2)200 to 499 (2.3 to 5.6)500 or more (5.6 or more)
ACC/AHA multisociety (2018)Not gradedNot gradedRisk enhancer if persistently 175 or more (1.97)Not graded
ACC/AHA multisociety (2026)Under 150 (1.7)Not usedMild to moderate 150 to 499 (1.7 to 5.6)Severe 500 or more; pancreatitis priority at 1,000 or more (11.3)
European Atherosclerosis Society consensus (2021)Optimal under about 100 (1.2)100 to 150 (1.2 to 1.7)Moderate 150 to 500 (1.7 to 5.7)Severe 500 to 880 (5.7 to 10); extreme over 880 (10)
EAS and EFLM lab flags (2016)Fasting under 150 (1.7); nonfasting under 175 (2.0)Not usedFlagged above those lines; retest fasting if nonfasting over 440 (5.0)Refer to a specialist if over 880 (10)
Endocrine Society (2012)Under 150 (1.7)Mild 150 to 199 (1.7 to 2.2)Moderate 200 to 999 (2.3 to 11.3)Severe 1,000 to 1,999 (11.3 to 22.6); very severe 2,000 or more

Triglyceride categories and guideline thresholds, mg/dL

OptimalHighVery highSevereOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLNormal, above optimal: 100 to 150 mg/dLNormal, above optimal: 100 to 150 mg/dLBorderline high: 150 to 200 mg/dLBorderline high: 150 to 200 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dLOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLOptimal: 0 to 100 mg/dLNormal, above optimal: 100 to 150 mg/dLNormal, above optimal: 100 to 150 mg/dLBorderline high: 150 to 200 mg/dLBorderline high: 150 to 200 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLHigh: 200 to 500 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLVery high: 500 to 1,000 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dLSevere: 1,000 to 1,100 mg/dL001001.1EAS optimal limit (1.2 mmol/L): 100 mg/dL1501.7AHA and NLA normal limit (1.7 mmol/L): 150 mg/dL1752ACC/AHA risk enhancer; nonfasting lab flag: 175 mg/dL2002.3ESC/EAS 2019 drug threshold in high risk: 200 mg/dL5005.6Very high (5.6 mmol/L): 500 mg/dL8809.9EAS pancreatitis risk (10 mmol/L): 880 mg/dL1,00011.3ACC/AHA 2026 pancreatitis priority: 1,000 mg/dL1,100 mg/dL12.4 mmol/L
Optimal
00 to 1001.1
Normal, above optimal
1001.1 to 1501.7
Borderline high
1501.7 to 2002.3
High
2002.3 to 5005.6
Very high
5005.6 to 1,00011.3
Severe
1,00011.3 to 1,10012.4
  • 100 mg/dL1.1 mmol/L: EAS optimal limit (1.2 mmol/L)
  • 150 mg/dL1.7 mmol/L: AHA and NLA normal limit (1.7 mmol/L)
  • 175 mg/dL2 mmol/L: ACC/AHA risk enhancer; nonfasting lab flag
  • 200 mg/dL2.3 mmol/L: ESC/EAS 2019 drug threshold in high risk
  • 500 mg/dL5.6 mmol/L: Very high (5.6 mmol/L)
  • 880 mg/dL9.9 mmol/L: EAS pancreatitis risk (10 mmol/L)
  • 1,000 mg/dL11.3 mmol/L: ACC/AHA 2026 pancreatitis priority
Most guidelines draw the normal line at 150 mg/dL (1.7 mmol/L) and the very high line at 500 mg/dL (5.6 mmol/L); pancreatitis risk takes over near 880 to 1,000 mg/dL.

What raises and lowers triglycerides?

Excess alcohol, sugar and refined starch, weight gain, poorly controlled diabetes, an underactive thyroid, kidney disease, pregnancy and some medicines raise triglycerides. Weight loss, exercise, less sugar and alcohol, and medicines such as statins, fibrates and prescription omega-3 lower them, but only some of these lower heart risk.

The 2026 US guideline review lists the usual secondary causes: poor blood sugar control, alcohol excess, obesity, an underactive thyroid, kidney disease, refined-carbohydrate intake, pregnancy and triglyceride-raising medicines [7]. Checking HbA1c and TSH is part of working out why a level is high.

Lifestyle levers

  • Weight: losing 5 to 10% of body weight lowers triglycerides by about 20% [1].
  • Diet quality: cutting trans fats, sugar, refined starch and alcohol and adding unsaturated fats and seafood lowers triglycerides by about 10 to 20% [1]. In trials, higher sugar intakes raised triglycerides by about 10 mg/dL (0.11 mmol/L)0.11 mmol/L (about 10 mg/dL) [21].
  • Alcohol: 30 g of alcohol a day raised triglycerides by 5.7 mg/dL on average [22]. People with very high levels are told to avoid alcohol altogether [7].
  • Exercise: aerobic training lowered triglycerides by 15 to 16 mg/dL (0.17 to 0.18 mmol/L)0.17 to 0.18 mmol/L (15 to 16 mg/dL) in sedentary adults with metabolic syndrome features [23].

The how to lower triglycerides page ranks every lever by effect size. AumniVIDA protocols that act on these habits include the Mediterranean pattern, glucose stability, keto and low-carb, time-restricted eating and Zone 2 base building.

Medicines: the triglyceride number and the heart do not always agree

Three large trials show the gap. In REDUCE-IT, 4 g a day of icosapent ethyl, a purified EPA drug, cut major cardiovascular events from 22.0% to 17.2% in statin-treated patients with triglycerides of 135 to 499 mg/dL, with more atrial fibrillation (3.1% vs 2.1%) [8]. In STRENGTH, 4 g a day of an EPA plus DHA drug did nothing for events (12.0% vs 12.2%) [9]. In PROMINENT, pemafibrate lowered triglycerides by 26.2% but raised ApoB by 4.8% and did not reduce events [10]. Across older fibrate trials, major events fell by 10% with no effect on deaths [24].

The 2026 US guideline review reads this as formulation-specific: icosapent ethyl may be considered in selected statin-treated adults with heart disease, or diabetes plus other risk factors, whose triglycerides stay at 150 to 499 mg/dL, and the result should not be extended to fish oil supplements [7]. Decisions about these drugs belong with your clinician.

Outcome trials of triglyceride-lowering drugs taken with statins. [8]
TrialTreatmentWho took partHeart outcome
REDUCE-IT (2019)Icosapent ethyl (EPA only), 4 g a day8,179 people with heart disease or diabetes plus risk factors, triglycerides 135 to 499 mg/dLEvents 17.2% vs 22.0%; hazard ratio 0.75
STRENGTH (2020)EPA plus DHA carboxylic acids, 4 g a day vs corn oil13,078 high-risk people, median triglycerides 240 mg/dLEvents 12.0% vs 12.2%; no benefit
PROMINENT (2022)Pemafibrate 0.2 mg twice a day10,497 people with type 2 diabetes, triglycerides 200 to 499 mg/dL, low HDLTriglycerides 26.2% lower, ApoB 4.8% higher; hazard ratio 1.03
A glass of red wine and a slice of cake on one side of a wooden table, a plate of grilled fish with green vegetables and olive oil on the other.
Alcohol, sugar and refined starch push triglycerides up, while fish, vegetables and unsaturated fats are part of the eating pattern guidelines recommend for high levels.

What does the evidence not show?

It does not show that lowering the triglyceride number by itself prevents heart attacks. Fibrate and mixed omega-3 trials found little or no benefit, the one clearly positive trial used a specific EPA drug, and no major guideline sets a triglyceride target for heart risk.

  • No heart-risk target. The 2019 European guideline sets no treatment goal for triglycerides or remnants because trials have not shown that lowering them reduces events [2]. Targets that do exist, such as under 500 mg/dL in NLA guidance or under 1,000 mg/dL in Endocrine Society guidance, aim at pancreatitis [1].
  • Lowering triglycerides without lowering ApoB may not help. PROMINENT cut triglycerides by about a quarter and raised ApoB slightly, with no change in events [10]. Genetic data predict exactly this [5].
  • REDUCE-IT is not a general fish oil result. Its benefit was larger than the modest triglyceride drop would predict, and STRENGTH, using EPA plus DHA, found none [7] [9].
  • Pancreatitis targets rest on association. Few trials compare triglyceride targets for preventing pancreatitis [7]. The olezarsen trials are the first large ones to show fewer pancreatitis attacks with treatment (rate ratio 0.15) [26].
  • Supplements vary. One analysis found that over-the-counter fish oils contained on average 68% of the EPA and DHA on the label [1].
  • Ratios are proxies. The triglyceride to HDL ratio did not identify insulin resistance in African-American women [27] or South Asian women [28].

How thinking about triglycerides changed, 2007 to 2026

  1. 2007

    Nonfasting triglycerides predict heart attacks in Copenhagen and US women

  2. 2009

    Pooled data: risk overlaps with HDL and non-HDL cholesterol

  3. 2012

    Endocrine Society guideline separates heart and pancreatitis ranges

  4. 2013

    Genetics point to remnant cholesterol as causal

  5. 2014

    APOC3 mutations: lower triglycerides, lower coronary risk

  6. 2016

    European consensus: fasting not routinely required

  7. 2019

    REDUCE-IT: icosapent ethyl cuts events by 25%

  8. 2019

    Benefit tracks ApoB, not triglycerides

  9. 2020

    STRENGTH: EPA plus DHA shows no benefit

  10. 2021

    EAS consensus on triglyceride-rich lipoproteins

  11. 2022

    PROMINENT: pemafibrate lowers triglycerides, not events

  12. 2025

    ApoC-III drugs cut triglycerides by more than half

  13. 2026

    Olezarsen reduces pancreatitis in severe hypertriglyceridemia

  14. 2026

    US guideline adds hypertriglyceridemia

Genetics moved triglyceride-rich particles from bystander to cause, while outcome trials showed that lowering the triglyceride number alone is not enough.

The research

Foundational studies

The work that established what this marker means.

Guidelines and reviews

Where expert bodies and systematic reviews have landed.

Recent research

Notable work from the last three years.

What well-known voices say about Triglycerides

Their positions, summarized in our words. Follow each link for the full context.

Watch

Talks and explainers worth your time. Nothing loads from YouTube until you press play.

  • What Are Triglycerides?

    Cleveland ClinicOpen on YouTube

    A plain-language introduction from a major academic medical center.

  • Mayo Clinic Minute - What high triglycerides mean and why it matters to your heart

    Mayo ClinicOpen on YouTube

    A one-minute cardiologist explanation of why high levels matter for the heart.

  • Lowering Triglycerides - Mayo Clinic

    Mayo ClinicOpen on YouTube

    An older but widely watched overview of the lifestyle steps that lower triglycerides.

  • Metabolism | Lipoprotein Metabolism | Chylomicrons, VLDL, IDL, LDL, & HDL

    Ninja NerdOpen on YouTube

    A detailed whiteboard lecture on how chylomicrons, VLDL and remnants are made and cleared.

  • CardioCore Lecture Triglycerides, Remnant Cholesterol, and Cardiovascular Risk

    ASPCOpen on YouTube

    A recent clinician lecture from the American Society for Preventive Cardiology on remnants and residual risk.

  • Triglyceride-rich lipoproteins and remnant cholesterol: unmet clinical needs.

    R3i FoundationOpen on YouTube

    A specialist talk on why remnant cholesterol matters after LDL is treated.

Protocols that act on Triglycerides

Common questions

What is the difference between triglycerides and cholesterol?

Triglycerides are fat used for energy; cholesterol is a building material for cells and hormones. Both travel in the same lipoprotein particles, and a standard lipid panel measures both [3].

Can triglycerides be high after eating?

Yes, a little. After ordinary meals the average rise is at most about 26 mg/dL (0.3 mmol/L)0.3 mmol/L (26 mg/dL) [3]. A very fatty meal can push one result much higher, and later tests are usually lower.

How many hours should you fast for a triglyceride test?

Most people do not need to fast. When a fasting test is asked for, the traditional fast is 8 to 12 hours with water allowed [3].

Do triglycerides change from day to day?

They vary more than cholesterol with meals and alcohol, but over years they are about as stable as blood pressure: within-person correlations were 0.64 over 4 years [12]. One high reading is worth repeating before drawing conclusions.

Do high triglycerides cause heart attacks?

Genetic studies suggest triglyceride-rich particles and their remnants cause heart disease [4]. The risk seems to follow the number of ApoB particles rather than the triglyceride number itself [5].

At what level do triglycerides cause pancreatitis?

European guidance puts the high-risk line at 880 mg/dL (10 mmol/L)10 mmol/L (880 mg/dL), with risk rising sharply above about 1,770 mg/dL (20 mmol/L)20 mmol/L (1,770 mg/dL) [2]. Risk already rises at lower levels: it was 8.7 times higher at 443 mg/dL (5 mmol/L)5 mmol/L (443 mg/dL) or more than under 89 mg/dL [6].

What is the difference between triglycerides and fatty acids?

A triglyceride is three fatty acids joined to glycerol. Lipoprotein lipase splits triglycerides in the blood so tissues can take up the fatty acids [2].

Is alcohol bad for triglycerides?

Alcohol raises them. In experimental studies, 30 g a day raised triglycerides by about 5.7 mg/dL on average [22], and people with very high levels are advised to avoid alcohol [7].

Can high triglycerides be reversed?

Often, because triglycerides respond quickly. Weight loss of 5 to 10% lowers them by about 20%, and diet changes by about 10 to 20% [1]. Genetic forms and very high levels usually also need medicine.

Sources

  1. 1.Karalis DG. A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Adv Ther, 2017. doi:10.1007/s12325-016-0462-y
  2. 2.Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J, 2021. doi:10.1093/eurheartj/ehab551
  3. 3.Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J, 2016. doi:10.1093/eurheartj/ehw152
  4. 4.Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol, 2013. doi:10.1016/j.jacc.2012.08.1026
  5. 5.Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA, 2019. doi:10.1001/jama.2018.20045
  6. 6.Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA Intern Med, 2016. doi:10.1001/jamainternmed.2016.6875
  7. 7.Sabouret P, Mafrica D, Giamundo DM, et al. The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management. Life (Basel), 2026. doi:10.3390/life16091470
  8. 8.Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019. doi:10.1056/NEJMoa1812792
  9. 9.Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA, 2020. doi:10.1001/jama.2020.22258
  10. 10.Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022. doi:10.1056/NEJMoa2210645
  11. 11.Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res, 2016. doi:10.1161/CIRCRESAHA.115.306249
  12. 12.Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation, 2007. doi:10.1161/CIRCULATIONAHA.106.637793
  13. 13.Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007. doi:10.1001/jama.298.3.299
  14. 14.Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009. doi:10.1001/jama.2009.1619
  15. 15.Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet, 2013. doi:10.1038/ng.2795
  16. 16.TG and HDL Working Group of the Exome Sequencing Project, NHLBI, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med, 2014. doi:10.1056/NEJMoa1307095
  17. 17.Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med, 2020. doi:10.1371/journal.pmed.1003062
  18. 18.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019. doi:10.1161/CIR.0000000000000625
  19. 19.Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007. doi:10.1001/jama.298.3.309
  20. 20.Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2012. doi:10.1210/jc.2011-3213
  21. 21.Te Morenga LA, Howatson AJ, Jones RM, Mann J. Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. Am J Clin Nutr, 2014. doi:10.3945/ajcn.113.081521
  22. 22.Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ, 1999. doi:10.1136/bmj.319.7224.1523
  23. 23.Wood G, Taylor E, Ng V, et al. Determining the effect size of aerobic exercise training on the standard lipid profile in sedentary adults with three or more metabolic syndrome factors: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med, 2021. doi:10.1136/bjsports-2021-103999
  24. 24.Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, 2010. doi:10.1016/S0140-6736(10)60656-3
  25. 25.McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am J Cardiol, 2005. doi:10.1016/j.amjcard.2005.03.085
  26. 26.Marston NA, Bergmark BA, Alexander VJ, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med, 2026. doi:10.1056/NEJMoa2512761
  27. 27.Sumner AE, Harman JL, Buxbaum SG, et al. The triglyceride/high-density lipoprotein cholesterol ratio fails to predict insulin resistance in African-American women: an analysis of Jackson Heart Study. Metab Syndr Relat Disord, 2010. doi:10.1089/met.2010.0028
  28. 28.Mostafa SA, Davies MJ, Morris DH, et al. The association of the triglyceride-to-HDL cholesterol ratio with insulin resistance in White European and South Asian men and women. PLoS One, 2012. doi:10.1371/journal.pone.0050931
  29. 29.Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2026. doi:10.1161/CIR.0000000000001423
  30. 30.Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019. doi:10.1161/CIR.0000000000000709
  31. 31.Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association. J Clin Lipidol, 2023. doi:10.1016/j.jacl.2023.05.099
  32. 32.Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med, 2014. doi:10.1056/NEJMoa1308027
  33. 33.Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol, 2016. doi:10.1016/j.amjcard.2016.02.011
  34. 34.Kelley GA, Kelley KS, Roberts S, Haskell W. Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Clin Nutr, 2012. doi:10.1016/j.clnu.2011.11.011
  35. 35.Mansoor N, Vinknes KJ, Veierod MB, Retterstol K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr, 2016. doi:10.1017/S0007114515004699
  36. 36.McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med, 2003. doi:10.7326/0003-4819-139-10-200311180-00007
  37. 37.Hanak V, Munoz J, Teague J, et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol, 2004. doi:10.1016/j.amjcard.2004.03.069
  38. 38.Baneu P, Vacarescu C, Dragan SR, et al. The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance. Biomedicines, 2024. doi:10.3390/biomedicines12071493
  39. 39.Norwitz NG, Feldman D, Soto-Mota A, et al. Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a "Lean Mass Hyper-Responder" Phenotype. Curr Dev Nutr, 2022. doi:10.1093/cdn/nzab144
  40. 40.Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr Opin Lipidol, 2020. doi:10.1097/MOL.0000000000000663
  41. 41.Kotwal A, Cortes T, Genere N, et al. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab, 2020. doi:10.1210/clinem/dgaa672
  42. 42.Bergmark BA, Marston NA, Prohaska TA, et al. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. N Engl J Med, 2025. doi:10.1056/NEJMoa2507227
  43. 43.Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N Engl J Med, 2025. doi:10.1056/NEJMoa2409368

AumniVIDA explains health data for general wellness. Talk to your clinician about your own results, medication and diagnosis.

Track your Triglycerides over time.

Bring every lab report into one history, compare results with your own baseline, and ask the coach what changed. Join the iPhone beta.

Join the iPhone beta. We send TestFlight invitations in batches.